AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05288946 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: traditional therapy
Description: the patients will receive exercise in the form of Sitting knee raise on gym ball to maintain stability in the presence of hip movement on a reduced base of support, abdominal slide to control action of the rectus abdominis while moving, Lying trunk curl with leg lift to strengthen upper and lower abdominals (figure 1-6), Basic superman to strengthen the spinal and hip extensors
Study NCT05288946 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: traditional therapy
Description: the patients will receive exercise in the form of Sitting knee raise on gym ball to maintain stability in the presence of hip movement on a reduced base of support, abdominal slide to control action of the rectus abdominis while moving, Lying trunk curl with leg lift to strengthen upper and lower abdominals (figure 1-6), Basic superman to strengthen the spinal and hip extensors
Study NCT06056635 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Karl Storz Curved Scope
Description: The curved fetoscope (11508AAK) will be used to view target areas during in-utero procedures for patients with a placenta that sits at the front of the uterus. There are various fetal conditions that may require use of a fetoscope during minimally invasive surgery. These include the need to seal vessels in order to stop blood flow going in a specific direction during pregnancy, abnormal vessels that may need to be sealed, or to break down scar tissue, extra tissue attachments, or blockages.
Study NCT06056635 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Karl Storz Straight Scope
Description: The straight fetoscope (11506AAK) will be used to view target areas during in-utero procedures for patients with a placenta that sits at the back of the uterus. There are various fetal conditions that may require use of a fetoscope during minimally invasive surgery. These include the need to seal vessels in order to stop blood flow going in a specific direction during pregnancy, abnormal vessels that may need to be sealed, or to break down scar tissue, extra tissue attachments, or blockages.
Study NCT06248307 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Barrita experimental
Description: Nutritional advice, as well as administration of protein bars.
Study NCT06248307 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Barrita Placebo
Description: Nutritional advice, as well as administration of placebo bars.
Study NCT05495386 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hyposafe hypoglycaemia notification device (H02)
Description: The H02 device consists of two parts:~1. An implantable part which records the EEG signal and transmits the signal wirelessly to the external device.~2. The external device receiving signals and storing data from the implant.
Study NCT05995587 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-based cognitive therapy (MBCT)
Description: MBCT combines mindfulness meditation with cognitive behavioural therapy (CBT) elements to reduce or prevent recurrent major depressive disorders.
Study NCT05022316 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CDS Tool Access
Description: Clinics receiving the intervention will have access to EHR-based CDS tools designed to support social risk-informed care. Prior to tool activation in participating community health centers (CHCs), clinic staff members will be oriented to the CDS tools by an EHR trainer (either on-site or remotely).
Study NCT05077904 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Staccato alprazolam
Description: Route of administration: Inhalation~Participants will receive one dose of Staccato alprazolam during the Treatment Period.
Study NCT05077904 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Route of administration: Inhalation~Participants will receive one dose of placebo during the Treatment Period.
Study NCT05266482 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Personal report
Description: In the intervention group, in addition to receiving the usual care, patients will receive personal reports on multiple time points. These reports include feedback on their PROs including reference scores of patients who previously underwent total knee replacement surgery.
Study NCT05654064 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Remifentanil-dexmedetomidine
Description: Compare adequacy of remifentanil-dexmedetomidine sedation protocols in pregnant patients undergoing minimally invasive fetoscopic procedures.
Study NCT05654064 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine-fentanyl
Description: Compare adequacy of dexmedetomidine-fentanyl sedation protocols in pregnant patients undergoing minimally invasive fetoscopic procedures.
Study NCT05793866 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: BUTEYKO RESPIRATORY TECHNIQUE
Description: Buteyko Breathing Technique In recent years, breathing exercises have been used as one of the non-pharmacological, alternative and/or complementary approaches in the management of many chronic diseases and conditions. Buteyko Breathing Technique (BST), Russian Dr. It was developed by Konstantin Buteyko in the 1950s. Dr. Buteyko evaluates the normal respiration over carbon dioxide, the respiratory holding time used in the technique is defined as a control pause, and this value shows the body's oxygenation and carbon dioxide tolerance. BST is a technique performed only through the nose, which includes respiratory control and respiratory hold after inhalation.
Study NCT04769232 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EG-760Z endoscope by Fujifilm
Description: Within a single endoscopic procedure under propofol sedation, images of the esophageal wall will be acquired and biopsies will be taken. All patients will be examined using the EG-760Z endoscope by Fujifilm.~In all patients as part of the clinical routine 4 biopsies of the proximal and 4 biopsies of the distal esophagus will be taken.
Study NCT04769232 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: EG-760Z endoscope by Fujifilm
Description: Within a single endoscopic procedure under propofol sedation, images of the esophageal wall will be acquired and biopsies will be taken. All patients will be examined using the EG-760Z endoscope by Fujifilm.~In all patients as part of the clinical routine 4 biopsies of the proximal and 4 biopsies of the distal esophagus will be taken.
Study NCT05534568 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Parent-Child Assistance Program
Description: Case managers work closely with mothers over the course of three years, meeting the mothers in their own homes when possible, to help them to set goals and take advantage of available resources.
Study NCT05454020 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XG004
Description: XG004 gel in two concentrations (5% and 10%) will be applied topically once-daily, twice-daily or three times daily in a designated area of the study knee.
Study NCT05454020 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo gel will be applied topically once-daily, twice-daily or three times daily in a designated area of the study knee.
Study NCT05691413 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Other: Product X facial cleanser
Description: Product X facial cleanser contain olive oil, virgin coconut oil, butylene glycol and hyaluronic acid
Study NCT04814589 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ezetimibe tablets
Description: The subjects randomly received single oral administration of ezetimibe tablets 10 mg.
Study NCT04814589 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ezetimibe tablets(Ezetrol ®)
Description: The subjects randomly received single oral administration of ezetimibe tablets 10 mg.
Study NCT05430802 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Furmonertinib+cisplating/pemetrexed
Description: Furmonertinib 80mg/d for 9 weeks and cisplating75mg/m2 d1 iv + pemetrexed 500mg/m2 d1 iv in 21-day cycles for 3 cycles
Study NCT04269720 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Biofeedback
Description: They will also be taught how to use the biofeedback app and Inner Balance device. Additionally, they will also be educated on the principles of biofeedback and its benefits and taught how to maximize HRV by using self-regulation breathing techniques, guided imagery, and/ or self-talk.They will be given an Inner Balance device, which is an ear sensor that connects to an apple device that measures heart rate variability (HRV) and gives them access to an app that is designed to help them improve their HRV. They will be asked to use this device daily for 10 mins for the duration of the 8-week intervention. Patients and the research coordinator will have access to all of their sessions and results. The research coordinator will monitor compliance via the Heartcloud associated with their device and encourage adherence throughout the 8-week biofeedback intervention.
Study NCT04826471 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DermoRelizema ecofoam
Description: DermoRelizema ecofoam, class II a medical device, topical compact mousse, to be applied 2 times per day during the 42 days of study duration
Study NCT03713671 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: gait analysis
Description: Computerized gait analysis system will use to evaluate spatio-temporal gait parameters
Study NCT05497765 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Silibinin extract, mixed power of pueraria, schisandra and salvia miltiorrhiza
Description: Take 4 tablets with warm water twice a day
Study NCT05497765 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Silibinin extract
Description: Take 4 tablets with warm water twice a day
Study NCT05497765 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Take 4 tablets with warm water twice a day
Study NCT06504862 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zongertinib
Description: Zongertinib
Study NCT06092528 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Inspiratory muscle training
Description: Inspiratory muscle training will be performed with Power Breathe®. Inspiratory muscle training will be given to the training group, starting from 50% of the MIP, and 2 sessions/day, 15 minutes/session. Patients will be asked to check breathing for 4-5 breaths after 8-10 consecutive breathing cycles. The patient will continue this cycle for 15 minutes.
Study NCT06504862 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabigatran-etexilate
Description: Dabigatran-etexilate
Study NCT06092528 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Upper extremity aerobic exercise training
Description: Upper extremity aerobic exercise training will be performed 3 days/week, 1 session/day, 15 min/session using arm ergometer device accompanied by a physiotherapist. Aerobic exercise training workload will be 60-80% of maximal heart rate. In this study, the perception of dyspnea will be between 3-4, arm fatigue and general fatigue perception will be between 5-6, warm-up and cool-down periods will be 5 minutes, and pedaling speed will be 40-50 rev/min, according to MBS.
Study NCT06092528 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lower extremity aerobic exercise training
Description: Lower extremity aerobic exercise training will be performed 3 days/week, 1 session/day, 15 minutes/session using the treadmill device, accompanied by a physiotherapist. Aerobic exercise training workload was set at 60-80% of maximal heart rate, dyspnea perception according to MBS was between 3-4, arm fatigue and general fatigue perception was between 5-6, and warm-up and cool-down periods were 5 minutes.
Study NCT06092528 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resistant exercise training
Description: Upper and lower additional limb strengthening training will be performed 3 days/week, 1 session/day, 10 repetitions/sessions from the first day by using bullion weights in the presence of a physiotherapist. The upper extremity strengthening program will consist of a progressive exercise program to strengthen the shoulder flexors and abductors, and the lower extremity strengthening program to strengthen the knee extensors. The training workload will be increased progressively. For strength training, the workload will be adjusted so that the perception of fatigue is between 4 and 6 according to MBS.
Study NCT06092528 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Thoracic expansion exercises
Description: The control group will be asked to do thoracic expansion exercises seven days/week and 120 pieces/day for six weeks.
Study NCT06504862 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Description: Rosuvastatin
Study NCT06504862 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin hydrochloride
Description: Metformin hydrochloride
Study NCT06504862 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Furosemide
Description: Furosemide
Study NCT06028126 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intermittent Superficial Parasternal Intercostal Plane Block - Experimental
Description: Catheter insertion will be performed by an anesthesiologist with regional block training immediately following skin closure in the operating room. Catheters will be inserted under ultrasound guidance, in a sterile fashion, with a high-frequency linear transducer which will be placed 1 cm lateral to the sternal border in the longitudinal plane in order to view the T4-T5 intercostal space. A Tuohy needle will be used to enter the superficial parasternal intercostal plane, with saline being injected to help visualize the plane between the pectoralis major and intercostal muscles. Subsequently, the catheters will be advanced into the plane, and secured on the skin.~Following initial bolus dosing at the time of catheter placement (20 mL 0.2% ropivacaine), intermittent boluses of 10 mL 0.2% ropivacaine per side will be delivered via catheters q6-8 hours for 48 hours post-catheter insertion.
Study NCT06028126 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Intermittent Superficial Parasternal Intercostal Plane Block - Sham
Description: Catheter insertion will be performed by an anesthesiologist with regional block training immediately following skin closure in the operating room. Catheters will be inserted under ultrasound guidance, in a sterile fashion, with a high-frequency linear transducer which will be placed 1 cm lateral to the sternal border in the longitudinal plane in order to view the T4-T5 intercostal space. A Tuohy needle will be used to enter the superficial parasternal intercostal plane, with saline being injected to help visualize the plane between the pectoralis major and intercostal muscles. Subsequently, the catheters will be advanced into the plane, and secured on the skin.~Following initial bolus dosing at the time of catheter placement (20 mL 0.9% Saline), intermittent boluses of 10 mL 0.9% Saline per side will be delivered via catheters q6-8 hours for 48 hours post-catheter insertion.
Study NCT06420245 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Orion TM Amniotic Membrane Allograft
Description: The intervention is a sterile allograft made from dehydrated extracellular matrix, designed to promote wound healing by providing a reliable and protective wound covering. Amniotic membranes are hypothesized to promote healing in open wounds by serving as a scaffold to support native tissue ingrowth, encouraging angiogenesis, and limiting microbial spread.
Study NCT06420245 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Standard of Care (SOC)
Description: Standard wound care entails surgical debridement as needed to remove all non-viable tissue, screening for infection and probing of the wound for bone, weekly application of a collagen alginate primary dressing, and off-loading using a removable diabetic offloading cam-walker or total contact cast.
Study NCT06420245 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care (SOC)
Description: Standard wound care entails surgical debridement as needed to remove all non-viable tissue, screening for infection and probing of the wound for bone, weekly application of a collagen alginate primary dressing, and off-loading using a removable diabetic offloading cam-walker or total contact cast.
Study NCT05462873 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: QEQ278
Description: Intravenous dosing of QEQ278
Study NCT05679453 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lornoxicam 8 Mg Oral Tablet
Description: Lornoxicam is a oxicam grup non-steroid antiinflamatuar drug
Study NCT05276102 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Emollient cream
Description: Commercially available emollient cream
Study NCT05767593 — intervention group
Intervention type: DEVICE
Intervention: Wearing Samsung smartwatch and filling out daily surveys
Description: Participants will wear a Samsung smartwatch and fill out daily surveys about their mood and depressive symptoms.
Study NCT05965765 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Total knee arthroplasty
Description: who got total knee arthroplasty because of osteoarthritis
Study NCT05965765 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Total knee arthroplasty
Description: who got total knee arthroplasty because of osteoarthritis
Study NCT05965765 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: osteoarthritis without surgery
Description: who has osteoarthritis and didn't get any surgery
Study NCT05965765 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: osteoarthritis without surgery
Description: who has osteoarthritis and didn't get any surgery
Study NCT06109753 — intervention group
Intervention type: PROCEDURE
Intervention: Robotically Assisted Laparoscopic Surgery
Description: robotically assisted surgeries of about 60-minute duration with additional 30 min for preparing with the measurement equipment before surgery and 15 post evaluation of the corresponding surgery
Study NCT06109753 — intervention group
Intervention type: PROCEDURE
Intervention: Conventional Laparoscopic Surgery
Description: conventional surgeries of about 60-minute duration with additional 30 min for preparing with the measurement equipment before surgery and 15 post evaluation of the corresponding surgery
Study NCT06532370 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Contingency Managment
Description: If the sample be methamphetamine negative, participant will be positively reinforced and offered incentives. Participants immediately draw the reinforcement slip of paper to receive a prize from a selection kept on-site. Approximately, half of the slips offer written praise (e.g. great job!). The other half of slips are then divided between low value (e.g. food gift cards, bus passes), medium value (e.g. prepaid cell phone, clothing gift cards), and a few large value rewards (e.g. iPad, jewelry). Should the sample be positive for methamphetamine, no reinforcement and/or incentive to be provided. Participant will be encouraged to continue to participate in CM program and follow-up on the next CM date.
Study NCT05965765 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: control group
Description: healthy people
Study NCT06439836 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo tumor biopsy
Study NCT06439836 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection
Study NCT06439836 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT
Study NCT06439836 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Emavusertib
Description: Given PO
Study NCT06439836 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI
Study NCT06439836 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV
Study NCT06439836 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET
Study NCT06360796 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [(14)C]ADC189
Description: Each subject take a single oral dose of about 45 mg (about 100 μCi) \[(14)C\]ADC189 on Day 1 of the study, and be observed by 504 hours.
Study NCT05810129 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: concentric-eccentric strength training
Description: Concentric-eccentric cross training in a 6-week immobilization period + 12-week standard kinesic therapy (2 times a week)
Study NCT05810129 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: eccentric strength training
Description: Eccentric cross training in immobilization period of 6 weeks + Standard kinesic therapy of 12 weeks (2 times a week)
Study NCT05810129 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: standard physical therapy
Description: Men with clavicle fracture immobilized for 6 weeks + standard physical therapy for 12 weeks
Study NCT05165160 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Blood sample
Description: Pre- and postoperative blood sample
Study NCT04676763 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Substance P
Description: Participants will receive Substance P
Study NCT04676763 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Normal Saline
Description: Participants will receive normal saline as Negative control
Study NCT04676763 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Histamine
Description: Participants will receive histamine as Positive control